“…In this issue of the Journal , Zapater and colleagues (pp. 1698–1706 ) shed light upon the phenotypes and therapeutic opportunities for mitigating CV risk in OSA ( 13 ). They reported the results of a secondary analysis of the ISAACC study, aimed at understanding the impact of moderate–severe OSA on the incidence of CV disease in 1,701 patients with ACS of different CV risk phenotypes ( 13 ).…”